We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
- Authors
Hershfield, M S; Callaghan, J T; Tassaneeyakul, W; Mushiroda, T; Thorn, C F; Klein, T E; Lee, M T M
- Abstract
Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.
- Publication
Clinical pharmacology and therapeutics, 2013, Vol 93, Issue 2, p153
- ISSN
1532-6535
- Publication type
Journal Article
- DOI
10.1038/clpt.2012.209